Policy
CEE GN is focused on genetics, genomics
and medical biotechnology and their medical, ethical, legal
and psycho-social implications in order to continue to develop
these areas (including diagnosis, prognosis, and treatment),
which will directly impact the increasing number of patients.
Central and Eastern European countries lag behind other EU
countries when it comes to the issue of health care and access,
and hence, the CEE GN strives to increase the research capacity
and the availability of treatments.
CEE GN works from the perspective of
the patient. CEE GN has no intention to work in the field
of disability and social support as there are other organisations
who have taken responsibility for these areas.
CEE GN intends to work synergistic with all others with an
interest in the field or genetic diseases, and contributes
to joint ventures when relevant to achieving the objectives
of the network. This includes scientific groups, institutions
and societies as well as industries.
CEE GN has a special interest in working
together with other patient alliances in CEE.
Priorities
According to the results of a needs assessment
survey, the following priorities have been established:
 |
Genetic diseases, including rare (orphan)
disorders for which treatment is available, and other
serious diseases for which therapy is not yet available
but an early diagnosis is of a high importance |
|
New EU and candidate countries to support EU accession |
|
Collaboration with other alliances and networks interested
in the objectives of the networks |
|
